Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Available NCT07759141

EAP for Deucrictibant Immediate-release

Conditions: Hereditary Angioedema

Sex: All

Ages: 12 Years – 75 Years

Sponsor: Pharvaris Netherlands B.V.

Summary

This is an expanded access program (EAP) designed to allow access to deucrictibant immediate-release (IR) capsule for eligible participants with hereditary angioedema (HAE) in the United States (US) and US territories who lack satisfactory alternative treatment options for on-demand treatment of HAE attacks, as determined by their treating physician.

Eligibility Criteria

Inclusion Criteria: * Provision of informed consent: Participants must provide written informed consent. Adolescents (≥12 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07759141). StuddyBuddy aggregates publicly available trial information.